Here are some key findings: Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Northwestern Now posed five questions to the study senior author Dr
It summarizes the major risks, frequent side effects, and primary contraindications
Some profile a 25-pound weight loss in 7 weeks
At Elite Primary Care, Dr
Chemical synthesis and subsequent in vivo evaluation of a GIP/GLP-1MK-801 co-agonist conjugate revealed enhanced weight loss in DIO mice compared with mice treated with the GIP/GLP-1 co-agonist alone (Extended Data Fig
GLP-1 medications that prevent or delay these outcomes can be cost-effective even at higher price points, which is the argument payers are increasingly accepting
